Topical nepafenac after intravitreal injection: a prospective double-masked randomized controlled trial.

Abstract

PURPOSE:

To evaluate if a single drop of nepafenac can reduce the ocular discomfort after intravitreal injections compared with placebo.

METHODS:

One hundred and twenty patients undergoing intravitreal injections of bevacizumab or ranibizumab received a drop of nepafenac or placebo (Systane Ultra) after the injection in a prospective, double-masked, randomized controlled design. Patients rated their pain levels from 0 to 3 (no pain, mild pain, moderate pain, severe pain) at 1 hour, 6 hours, and 24 hours after the procedure.

RESULTS:

Statistically significant reduction of postinjection pain with nepafenac was noted 6 hours after the injection when compared with placebo (0.8 ± 0.6 [standard deviation] vs. 1.3 ± 0.8, P < 0.001) with similar trends at 1 hour (1.1 ± 0.7 vs. 1.3 ± 0.7, P = 0.12) and 24 hours (0.3 ± 0.5 vs. 0.5 ± 0.6, P = 0.15).

CONCLUSION:

A single drop of nepafenac is effective in reducing discomfort after intravitreal injections.

• Authors: J Niklas Ulrich
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 34 Issue 3 Pg. 509-11 (Mar 2014) ISSN: 1539-2864 [Electronic] United States
• PMID: 23928675 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Anti-Inflammatory Agents, Non-Steroidal
• Benzeneacetamides
• Phenylacetates
• nepafenac

Topics

• Administration, Topical
• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (administration & dosage)
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)
• Benzeneacetamides (administration & dosage)
• Double-Blind Method
• Eye Pain (drug therapy, etiology)
• Female
• Humans
• Intravitreal Injections (adverse effects)
• Male
• Pain Measurement
• Phenylacetates (administration & dosage)
• Prospective Studies